SCHEMBL6039385

SCHEMBL6039385

CC(=O)C(=O)N1CCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
ATM Q13315 1/20 0.40
HPGD P15428 3/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
CA2 P00918 1/20 0.37
CHKA P35790 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
CYP1A2 P05177 1/20 0.36
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35
GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3999543 0.97 ALDH1A1 (0.50) ALDH1A1ATMHPGDMMP1MMP2
SCHEMBL11284764 0.97 ALDH1A1 (0.50) ALDH1A1ATMHPGDMMP1MMP2
SCHEMBL15192539 0.94
SCHEMBL3736701 0.82 ALDH1A1 (0.52) ALDH1A1ATMHPGDMMP1MMP2
SCHEMBL8288869 0.81 ALDH1A1 (0.56) ALDH1A1ATMHPGDMMP1MMP2
SCHEMBL19484952 0.80 CYP1A2 (0.59) ALDH1A1HPGDMEN1KMT2ATDP1
SCHEMBL109476 0.78 ALDH1A1 (0.42) ALDH1A1ATMHPGDMMP1MMP2
SCHEMBL10121133 0.78 CYP1A2 (0.64) HPGDKMT2ATDP1LMNAGAA
SCHEMBL11889662 0.78 ALDH1A1 (0.58) ALDH1A1ATMHPGDMMP1MMP2
SCHEMBL4840666 0.78 ALDH1A1 (0.61) ALDH1A1ATMHPGDMMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101618462-B Method for producing metal nanoparticles DONGJIN SEMICHEM CO LTD 2014-09-10 CN claimed
CN-101618462-A Method for manufacturing metal nanometer particle DONGJIN SEMICHEM CO LTD 2010-01-06 CN claimed
US-20190092771-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2019-03-28 US disclosed
US-10174026-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-01-08 US disclosed
EP-2968282-B1 HISTONE DEMENTHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2018-05-09 EP disclosed
US-20180105521-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-04-19 US disclosed
US-9873697-B2 Histone demethylase inhibitors Celgene Quantical Research, Inc. (US) 2018-01-23 US disclosed
US-20170313702-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-11-02 US disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 US disclosed
US-9738637-B2 Histone demethylase inhibitors Celgene Quantical Research, Inc. (US) 2017-08-22 US disclosed
US-20160199355-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MAYERS SQUIBB COMPANY (US) 2016-07-14 US disclosed
CN-101618462-B Method for producing metal nanoparticles DONGJIN SEMICHEM CO LTD 2014-09-10 CN disclosed
US-20130183269-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 US disclosed
CN-101618462-A Method for manufacturing metal nanometer particle DONGJIN SEMICHEM CO LTD 2010-01-06 CN disclosed
CN-1929921-A Use of a composition comprising metal complex compounds and polyphosphonates as catalysts for oxidations CIBA SC HOLDING AG (CH) 2007-03-14 CN disclosed
CN-1929920-A Use of metal complex compounds comprising pyridine, pyrimidine or S-triazine derived ligands as catalysts for oxidations with organic peroxy acids and/or precursors of organic peroxy acids and H2O2 CIBA SC HOLDING AG (CH) 2007-03-14 CN disclosed
EP-1276491-B9 TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM UNIV PENNSYLVANIA (US) 2007-02-28 EP disclosed
WO-2006038001-A1 AMINOPYRIMIDINE DERIVATIVES AS JNK INHIBITORS CELLTECH R & D LIMITED (GB) 2006-04-13 WO disclosed
CN-1252806-A Dolastatin-15 derivatives having carbonyl and heterocyclic functional groups at the C-terminus BASF AG (DE) 2000-05-10 CN disclosed
CN-1252085-A Fluorescent compositions and their use CIBA SC HOLDING AG (CH) 2000-05-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313702-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A ALDH1A1 437/4885ATM 2933/4885HPGD 355/4885
US-20130183269-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, EIF2AK2 ALDH1A1 3966/4885ATM 3039/4885HPGD 3868/4885
US-20190092771-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A ALDH1A1 437/4885ATM 2933/4885HPGD 355/4885
US-20160199355-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, MAVS, EIF2AK2 ALDH1A1 3966/4885ATM 3039/4885HPGD 3868/4885
US-20180105521-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A ALDH1A1 437/4885ATM 2933/4885HPGD 355/4885
US-10174026-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5A ALDH1A1 437/4885ATM 2933/4885HPGD 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.